The preclinical biology of a new potent and selective progestin: trimegestone.
about
The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk.Sex differences in cognitive impairment and Alzheimer's disease.Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effectsMolecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget.New progestagens for contraceptive use.Pharmacology of different progestogens: the special case of drospirenone.Progesterone and neuroprotectionDoes hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study.Preclinical and clinical properties of trimegestone: a potent and selective progestin.Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy.A review of the cardiovascular and breast actions of drospirenone in preclinical studies.Contraceptives with novel benefits.Advances in neurosteroids: role in clinical practice.Neurosteroids in clinical practice: implications for women's health.Current state of hormone replacement therapy: the case for using trimegestone.Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies.Interaction Between Progesterone and Interleukin-1β in Modulating Progesterone Receptor Expression and the Inflammatory Phenotype in Human Cervical Fibroblasts.
P2860
Q30485457-65434E17-F99B-403A-B155-8A73D93A75B1Q33864547-53416329-6CB6-4DBD-BECD-881A5D308E39Q34317537-A7B034C6-6BC9-4AF0-A93F-92E2FD01B42FQ34424008-C3F738D2-782E-4BDD-A757-205383620461Q34468158-B996D4C7-EF7B-4B33-B1F6-CE77F260754FQ36276322-2FC22373-C4CA-4641-97EE-0E3E112E5F60Q36306281-28750E42-A9AB-4E5C-859B-6CBBC35E20BCQ36797854-19AB4EB8-6215-463D-B03F-6BF07F716A5DQ36872678-A824B323-8008-4A78-BE28-33D7A744C92CQ36902093-51DD4A5B-15FE-47DA-BE1B-96F16A1B0B29Q37638712-89B330A3-76EF-4CFD-AED3-2F8D35A50912Q37965736-F442F926-ABE4-4043-B034-70C1B106B0BCQ38121153-A990573C-1C07-4D74-A0ED-594D8EEE22D3Q38471653-78F4DAC8-CBEA-4B43-80CC-D0DC5C8E826CQ43267040-DC0F5586-410E-4FC7-9F7F-24327D326398Q47134980-4CF80E85-C41C-40FB-83E9-3409F4437BB5Q47936486-2A495772-6D5B-43F9-B3AA-EEFE0F0BBC80
P2860
The preclinical biology of a new potent and selective progestin: trimegestone.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The preclinical biology of a new potent and selective progestin: trimegestone.
@ast
The preclinical biology of a new potent and selective progestin: trimegestone.
@en
The preclinical biology of a new potent and selective progestin: trimegestone.
@nl
type
label
The preclinical biology of a new potent and selective progestin: trimegestone.
@ast
The preclinical biology of a new potent and selective progestin: trimegestone.
@en
The preclinical biology of a new potent and selective progestin: trimegestone.
@nl
prefLabel
The preclinical biology of a new potent and selective progestin: trimegestone.
@ast
The preclinical biology of a new potent and selective progestin: trimegestone.
@en
The preclinical biology of a new potent and selective progestin: trimegestone.
@nl
P2093
P1433
P1476
The preclinical biology of a new potent and selective progestin: trimegestone.
@en
P2093
Daniel Bitran
Richard C Winneker
Zhiming Zhang
P304
P356
10.1016/S0039-128X(03)00142-9
P577
2003-11-01T00:00:00Z